Self-administration of bretazenil under progressive-ratio schedules: behavioral economic analysis of the role intrinsic efficacy plays in the reinforcing effects of benzodiazepines.
Previous research suggests that intrinsic efficacy of benzodiazepines is an important determinant of their behavioral effects. We evaluated the reinforcing effects of the benzodiazepine partial agonist bretazenil using behavioral economic models referred to as "consumer demand" and "labor supply". Four rhesus monkeys were trained under a progressive-ratio (PR) schedule of i.v. midazolam injection. A range of doses of bretazenil (0.001-0.03 mg/kg/injection and vehicle) was evaluated for self-administration with an initial response requirement of 40 that doubled to 640; significant self-administration was maintained at doses of 0.003-0.03 mg/kg/injection. Next, a dose of bretazenil that maintained peak injections/session was made available with initial response requirements doubling from 10 to 320 (maximum possible response requirements of 160 and 5120, respectively), and increasing response requirements decreased self-administration (mean number of injections/session) of a peak dose (0.01 mg/kg/injection). Analyses based on consumer demand revealed that a measure of reinforcing strength termed "essential value", for bretazenil was similar to that previously obtained with midazolam (non-selective full agonist), but less than that observed for zolpidem (full agonist, selective for α1 subunit-containing GABA(A) receptors). According to labor supply analysis, the reinforcing effects of bretazenil were influenced by the economic concept referred to as a "price effect", similar to our previous findings with midazolam but not zolpidem. In general, behavioral economic indicators of reinforcing effectiveness did not differentiate bretazenil from a non-selective full agonist. These findings raise the possibility that degree of intrinsic efficacy of a benzodiazepine agonist may not be predictive of relative reinforcing effectiveness.
Licata
Stephanie C
SC
McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA.
Rowlett
James K
JK
D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008253:Macaca mulatta; D008297:Male; D018803:Models, Economic; D012055:Reinforcement Schedule; D012054:Reinforcement, Psychology; D012646:Self Administration
D001570:Benzodiazepinones; D001569:Benzodiazepines; C054626:bretazenil
Biochem Soc Symp. 1993;59:121-34
7910739
Exp Clin Psychopharmacol. 2007 Aug;15(4):328-37
17696679
J Exp Anal Behav. 1988 Nov;50(3):419-40
3209958
Mol Interv. 2005 Feb;5(1):20-8
15731502
J Pharmacol Exp Ther. 1997 Oct;283(1):29-38
9336305
Psychopharmacology (Berl). 2000 Dec;153(1):139-47
11255924
Cell Tissue Res. 2006 Nov;326(2):505-16
16937111
J Exp Anal Behav. 1995 Nov;64(3):361-71
8551193
Clin Pharmacol Ther. 1994 Apr;55(4):451-63
8162672
Exp Clin Psychopharmacol. 2002 Nov;10(4):367-75
12498333
Psychopharmacology (Berl). 2000 Dec;153(1):1-16
11255919
Eur J Pharmacol. 1990 Nov 6;190(1-2):269-73
1981753
J Exp Anal Behav. 1993 Jul;60(1):129-140
16812695
Pharmacol Biochem Behav. 1999 Oct;64(2):237-43
10515297
J Pharmacol Exp Ther. 1995 Oct;275(1):183-93
7562548
Br J Pharmacol. 1989 Nov;98(3):735-40
2574062
Psychol Rev. 2008 Jan;115(1):186-98
18211190
J Exp Anal Behav. 1995 Nov;64(3):373-84
8551194
Psychopharmacology (Berl). 1993;111(4):415-22
7870982
Life Sci. 1990;47(17):1501-10
2250566
Psychopharmacology (Berl). 2000 Dec;153(1):44-56
11255928
Curr Protoc Neurosci. 2005 Aug;Chapter 9:Unit 9.21
18428630
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):915-20
15644443
J Pharmacol Exp Ther. 2006 Mar;316(3):1378-85
16352707
J Pharmacol Exp Ther. 1995 Oct;275(1):405-11
7562578
Psychopharmacology (Berl). 1996 Dec;128(3):265-73
8972546
Pharmacol Biochem Behav. 1991 May;39(1):129-32
1924494
J Pharmacol Exp Ther. 1992 Jun;261(3):1113-21
1318371
Drug Alcohol Depend. 2005 Jul;79(1):53-62
15943944
Psychopharmacology (Berl). 1994 Mar;114(2):191-9
7838907
J Pharmacol Exp Ther. 1992 Jun;261(3):1106-12
1318370
Mol Pharmacol. 1993 Feb;43(2):240-4
8381510
J Pharmacol Exp Ther. 2006 Mar;316(3):1291-9
16339395
MMWR Morb Mortal Wkly Rep. 2010 Jun 18;59(23):705-9
20559200
J Pharmacol Exp Ther. 1992 Mar;260(3):1199-208
1312162
Nature. 2010 Feb 11;463(7282):769-74
20148031
Br J Pharmacol. 2006 Feb;147(3):260-8
16331290
Pharmacopsychiatry. 1988 Nov;21(6):360-2
2907644
Pharmacol Biochem Behav. 1994 Jun;48(2):397-401
8090806
Behav Pharmacol. 1999 Feb;10(1):39-50
10780301
Psychopharmacology (Berl). 2002 Oct;163(3-4):477-87
12373448